Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer

BACKGROUND: Systemic androgen deprivation therapy (ADT), also referred to as hormone therapy, has long been the primary treatment for metastatic prostate cancer. Additional agents have been reserved for the castrate‐resistant disease stage when ADT start becoming less effective. Abiraterone is an ag...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cochrane Database Syst Rev
Main Authors: Sathianathen, Niranjan J, Oestreich, Makinna C, Brown, Sarah Jane, Gupta, Shilpa, Konety, Badrinath R, Dahm, Philipp, Kunath, Frank
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Ltd 2020
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8092456/
https://ncbi.nlm.nih.gov/pubmed/33314020
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD013245.pub2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares